Syngene Shares Slide After Muted FY26 Outlook

As on 24th April 2025, shares price of

fell 10% on Thursday after the company issued a cautious revenue forecast for FY26. CEO Peter Bains projected early-teen growth, driven by broad-based gains across research, development, and manufacturing. However, adjusting for inventory balancing in large molecule manufacturing, growth could slow to mid-single digits. The stock has already declined 21.36% in 2025 and is down nearly 30% from its 52-week high, reflecting investor concern over slowing momentum. The outlook suggests headwinds ahead despite continued demand across business segments. Investors may stay cautious amid muted near-term growth expectations. Disclaimer: This post is for informational purposes only and does not constitute investment advice.